Introduction:There are two types of herpes simplex virus (HSV): HSV Type 1 (HSV-1) and HSV Type 1 (HSV-2). Viral comorbidity in HIV is on the increase. This study determines the seroprevalence of HSV 1 and 2 among immunodeficient patients in Gwagwalada, Nigeria.Materials and Methods:This is a hospital-based descriptive cross-sectional study which spanned 24 months from October 2014 to September 2016. A total of 160 HIV seropositive patients were recruited from venereology clinic.Results:The overall prevalence of herpes simplex infection among HIV seropositive patients in this study was 13.8%, the prevalence of herpes simplex Type 1 was 63.6%, while that of herpes simplex Type 2 was 36.4%. The mean age of the patients was 29 ± 13.9 years and the male-to-female ratio was 1:2. There were 52 male (32.5%) and 108 female (67.5%) seropositives. Among the 22 patients with positive HSV result, seven representing 31.8% were males, while 15 (68.2%) were females. The buttock was the predominant site of the body affected by herpes lesions in 7 of the patients representing 31.8%, four of these patients were infected with herpes simplex Type 2, while three representing 21.4% were herpes simplex Type 1. Other body sites are labia/penile (18.1%), oral (22.7%), and nasal (13.6%). In association with CD4 counts, five (35.7%) Herpes simplex Type 1 was isolated from patients with CD4 counts of 200–500 cell/mm and >500 cells/mm, respectively. The seroprevalence of herpes simplex Type 2 among patients with CD4 counts of <200 cell/mm was 62.5%.Conclusion:Herpes simplex infections are important viral comorbidity among HIV patients; this was more observed among females. Sexual practice play an important role with the occurrence of HSV-1 in patients with genital rash and predominance of buttock lesion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.